Specify a stock or a cryptocurrency in the search bar to get a summary
Sera Prognostics Inc
SERASera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. Address: 2749 East Parleys Way, Salt Lake City, UT, United States, 84109
Analytics
WallStreet Target Price
2.75 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SERA
Dividend Analytics SERA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SERA
Stock Valuation SERA
Financials SERA
Results | 2019 | Dynamics |